Table 4. Association of baseline and follow-up sTNF-R1 measurements with cardiovascular mortality estimated by using Cox regression models.

		Adjusted cause-specific HR (95% CI) Model 1	Adjusted cause-specific HR (95% CI) Model 2	Adjusted cause-specific HR (95% CI) Model 3	Adjusted cause-specific HR (95% CI) Model 4	Adjusted cause-specific H (95% CI) Model 5 With CRP/IL-6
All Subjects	Baseline sTNF-R1	1.22 (0.5–3.0)	1.15 (0.5–2.9)	1.25 (0.5–3.1)	1.26 (0.5–3.2)	1.70 (0.6–4.9)
	Follow-up sTNF-R1	2.76 (1.4–5.3)	2.76 (1.4–5.5)	3.76 (1.8–8.1)	4.13 (1.8–9.6)	2.93 (1.1–7.9)
Subjects without signs of acute inflammation *	Baseline sTNF-R1	0.70 (0.3–2.0)	0.60 (0.2–1.6)	0.60 (0.2–1.8)	0.60 (0.2–1.8)	0.9 (0.3–2.7)
	Follow-up sTNF-R1	5.33 (2.4–11.9)	4.93 (2.2–11.1)	9.5 (3.6–25.2)	8.7 (3.2–23.7)	6.5 (2.2–19.1)

Baseline and Follow-up measurements were included in each model. Model 1 is adjusted for age, sex. Model 2 is adjusted for age, sex and lifestyle risk factors: BMI, smoking, physical activity. Model 3 is adjusted for age, sex, and comorbidities: GFR value, hypertension, myocardial infarction (self-reported), diabetes mellitus 2, chronic heart failure, cancer, rheumatism and medication intake. Model 4 is adjusted for age, sex, lifestyle risk factors and comorbidities. Model 5 is adjusted for all covariates in Model 4 and additionally adjusted for IL-6, hsCRP, triglycerides, total, low- and high-density lipoprotein cholesterol level. HR Hazard Ratio, CI Confidence Interval. Bold indicates statistical significance.

*All subjects with hsCRP values > 10 mg/L at either baseline or follow-up or both were excluded.